Ligand Pharmaceuticals | LGND - Operating Profit


Ligand Pharmaceuticals reported $158.89M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Enviri Corporation USD -35.28M 61.58M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Merck USD 6.24B 318M Dec/2025
Pacira USD 3.19M 9.96M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 24.63M 1.52M Dec/2025